title: [Clinical characteristics of patients with IgA nephropathy and long-term survival after dialysis therapy].
abstract: OBJECTIVE
  Little is known about the treatment and clinical status of patients with biopsy-proven IgA nephropathy (IgAN) during long-term maintenance dialysis.
  
  
  METHODS
  Fifty-two of 433 patients with IgAN who had favorable survival rates of 93.3% and 65.1% at 10 and 20 years, respectively, in a previous study and had reached end-stage kidney disease were followed up for 11.1 ± 6.2 years. Forty of the 52 patients undergoing hemodialysis (HD) or peritoneal dialysis (PD) at the final observation in February 2012 were eligible for entry in this study. Laboratory findings, treatments and complications during the long-term follow-up were analyzed.
  
  
  RESULTS
  Mean age at starting dialysis (HD, n = 39; PD, n = 1) was 44.2 ± 13.1 years. Vascular access was achieved through an arteriovenous fistula in 95% of the 39 patients. Prescription rates of anti-hypertensive agents (68%), anti-platelet agents (35%), and statins (15%) were relatively low. The cardiothoracic ratio was well-controlled (< 50%) in about 60% of all patients and mean values for hemoglobin (10.6 ± 1.31 g/dL), adjusted calcium (9.56 ± 0.81 mg/dL), phosphate(5.89 ± 1.64 mg/dL), and intact-PTH (186 ± 221 pg/mL) were within the treatment goals recommended by Japanese guidelines. Complications during follow-up comprised cardiovascular events (n = 11), malignancy (n = 4), diabetes (n = 2), and arterial fibrillation (n = 2). Patients who remained on dialysis for > 10 years (n = 22) had started dialysis when they were significantly younger, and had a higher rate of onset of malignancy and of intact PTH values than those who were on dialysis for < 10 years (n = 18).
  
  
  CONCLUSIONS
  Patients with IgAN who remain on dialysis over the long-term can maintain stable and favorable clinical findings although the occurrence of malignant complications and bone mineral metabolic disorder should be monitored.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Komatsu
authors.forename: Hideto
authors.initials: H
authors.lastname: Nakagawa
authors.forename: Takashi
authors.initials: T
authors.lastname: Iwakiri
authors.forename: Tatsunori
authors.initials: T
authors.lastname: Toida
authors.forename: Akihiro
authors.initials: A
authors.lastname: Fukuda
authors.forename: Masao
authors.initials: M
authors.lastname: Kikuchi
authors.forename: Yuji
authors.initials: Y
authors.lastname: Sato
authors.forename: Kazuo
authors.initials: K
authors.lastname: Kitamura
authors.forename: Shouichi
authors.initials: S
authors.lastname: Fujimoto
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D005922:Glomerulonephritis, IGA / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000379:methods; D013995:Time; D016896:Treatment Outcome
chemical_list: D006454:Hemoglobins